Country: Israel
Language: English
Source: Ministry of Health
BRIMONIDINE TARTRATE
ABBVIE BIOPHARMACEUTICALS LTD, ISRAEL
S01EA05
OPHTHALMIC SOLUTION
BRIMONIDINE TARTRATE 0.15 %W/V
OCULAR
Required
ALLERGAN INC., USA
BRIMONIDINE
BRIMONIDINE
Alphagan is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
2014-06-30
ALP APL APR 23 CL Page 1 of 6 PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS (PREPARATIONS) - 1986 This medicine is dispensed with a doctor’s prescription only ALPHAGAN ® P OPHTHALMIC SOLUTION THE ACTIVE INGREDIENT AND ITS CONCENTRATION: brimonidine tartrate 0.15% w/v Inactive ingredients and allergens in this medicine: See section 6 ’ Additional information ‘. READ THE ENTIRE LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE. This leaflet contains concise information about this medicine. If you have any further questions, consult your doctor or pharmacist. This medicine has been prescribed to treat your illness/for you. Do not pass it on to others. It may harm them, even if it seems to you that their illness/medical condition is similar to yours. 1. WHAT IS THIS MEDICINE INTENDED FOR? Alphagan P is indicated for lowering intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension. THERAPEUTIC GROUP: alpha-adrenergic receptor agonists. 2. BEFORE USING THIS MEDICINE DO NOT USE THIS MEDICINE IF: − You are sensitive (allergic) to the active ingredient brimonidine tartrate or any of the other ingredients in this medicine (listed in section 6 ’ Additional information ’ ). − In neonates and infants (under the age of 2 years). SPECIAL WARNINGS ABOUT USING THIS MEDICINE BEFORE TREATMENT WITH ALPHAGAN P, TELL YOUR DOCTOR IF: ALP APL APR 23 CL Page 2 of 6 • You have, or had in the past kidney or liver problems. • You have, or had in the past heart problems. • You are suffering, or have suffered in the past, from depression, decreased mental capacities, decreased blood supply to the brain, or a blood pressure disorder. • You are suffering, or have suffered in the past, from blood circulation problems which make the toes and fingers numb and pale. This is called Raynaud’s phenomenon. CHILDREN AND ADOLESCENTS Do not use Alphagan P in neonates and infants under the age of 2 years. DRUG INTERACTIONS IF YOU ARE TAKING OR HAVE RECENTLY TAKEN OTHER MEDICINES Read the complete document
ALP API APR 23 CL Page 1 of 6 1 NAME OF THE MEDICINAL PRODUCT ALPHAGAN ® P 2 QUALITATIVE AND QUANTITATIVE COMPOSITION brimonidine tartrate 0.15% w/v For the full list of excipients, see section 12. 3 PHARMACEUTICAL FORM ophthalmic solution 4 INDICATIONS AND USAGE ALPHAGAN® P is indicated for lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. 5 DOSAGE AND ADMINISTRATION The recommended dose is one drop of ALPHAGAN ® P in the affected eye(s) three times daily, approximately 8 hours apart. ALPHAGAN ® P ophthalmic solution may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic product is to be used, the different products should be instilled at least 5 minutes apart. 6 CONTRAINDICATIONS 6.1 NEONATES AND INFANTS (UNDER THE AGE OF 2 YEARS) ALPHAGAN ® P is contraindicated in neonates and infants (under the age of 2 years). 6.2 HYPERSENSITIVITY REACTIONS ALPHAGAN ® P is contraindicated in case of hypersensitivity to the active substance or to any of the excipients listed in section 12. 7 WARNINGS AND PRECAUTIONS 7.1 POTENTIATION OF VASCULAR INSUFFICIENCY ALPHAGAN ® P may potentiate syndromes associated with vascular insufficiency. ALPHAGAN ® P should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud ’ s phenomenon, orthostatic hypotension, or thromboangiitis obliterans. 7.2 SEVERE CARDIOVASCULAR DISEASE Although brimonidine tartrate ophthalmic solution had minimal effect on the blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease. 7.3 CONTAMINATION OF TOPICAL OPHTHALMIC PRODUCTS AFTER USE There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular ep Read the complete document